E-viri
Recenzirano
-
Ahn, Jin Young, MD; Song, Je Eun, MD; Kim, Min Hyung, MD; Choi, Heun, MD; Kim, Jae Kyung, MD; Ann, Hea Won, MD; Kim, Jung Ho, MD; Jeon, Yongduk, MD; Jeong, Su Jin, MD, PhD; Kim, Sun Bean, MD; Ku, Nam Su, MD; Han, Sang Hoon, MD, PhD; Song, Young Goo, MD, PhD; Yong, Dongeun, MD, PhD; Lee, Kyungwon, MD, PhD; Kim, June Myung, MD, PhD; Choi, Jun Yong, MD, PhD
American journal of infection control, 06/2014, Letnik: 42, Številka: 6Journal Article
Background Carbapenem resistance among gram-negative bacilli is an emerging threat worldwide. The objective of this study was to identify risk factors for the acquisition of carbapenem-resistant Escherichia coli (CRE). Methods We conducted a matched case-control study comprising 57 cases of acquisition of CRE and 114 controls (1:2 matched) selected from patients with a culture of carbapenem-susceptible E coli between January 2006 and December 2010 at a 2000-bed tertiary care center in South Korea. Results On univariate analysis, previous use of carbapenem ( P < .01), fluoroquinolone ( P < .01), and glycopeptide ( P < .01), as well as length of hospital stay ( P < .05), were significantly associated with CRE acquisition. On multivariate analysis, previous use of carbapenem (odds ratio OR, 4.56; 95% confidence interval CI 1.44-14.46; P = .01) and previous use of fluoroquinolone (OR, 2.81; 95% CI, 1.14-6.99; P = .03) were independent risk factors. Conclusions At this institute, the antibiotic selective pressure of carbapenems and fluoroquinolones was shown to be an important risk factor for the acquisition of CRE.
